Fagron SA (ARSUF)
18.59
0.00 (0.00%)
USD |
OTCM |
May 16, 16:00
Fagron Total Liabilities (Quarterly): 596.17M for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 596.17M |
| June 30, 2023 | 634.86M |
| June 30, 2023 | 634.86M |
| December 31, 2022 | 601.07M |
| June 30, 2022 | 607.42M |
| June 30, 2022 | 607.42M |
| December 31, 2021 | 537.75M |
| June 30, 2021 | 598.05M |
| June 30, 2021 | 598.05M |
| December 31, 2020 | 608.84M |
| June 30, 2020 | 651.89M |
| June 30, 2020 | 651.89M |
| December 31, 2019 | 621.47M |
| June 30, 2019 | 623.33M |
| June 30, 2019 | 623.33M |
| December 31, 2018 | 541.13M |
| June 30, 2018 | 573.45M |
| June 30, 2018 | 573.45M |
| December 31, 2017 | 490.88M |
| June 30, 2017 | 764.01M |
| June 30, 2017 | 764.01M |
| Date | Value |
|---|---|
| December 31, 2016 | 756.06M |
| June 30, 2016 | 789.90M |
| June 30, 2016 | 789.90M |
| December 31, 2015 | 824.52M |
| June 30, 2015 | 866.32M |
| June 30, 2015 | 866.32M |
| December 31, 2014 | 993.26M |
| June 30, 2014 | 1.121B |
| June 30, 2014 | 1.121B |
| December 31, 2013 | 896.92M |
| June 30, 2013 | 812.35M |
| June 30, 2013 | 812.35M |
| December 31, 2012 | 666.16M |
| June 30, 2012 | 577.78M |
| June 30, 2012 | 577.78M |
| December 31, 2011 | 593.82M |
| June 30, 2011 | 557.45M |
| December 31, 2010 | 486.06M |
| June 30, 2010 | 363.39M |
| December 31, 2009 | 394.41M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
537.75M
Minimum
Dec 2021
651.89M
Maximum
Jun 2020
613.09M
Average
608.84M
Median
Dec 2020
Total Liabilities (Quarterly) Benchmarks
| uniQure NV | 623.30M |
| ProQR Therapeutics NV | 96.17M |
| Merus NV | 148.64M |
| argenx SE | -- |
| Pharming Group | 235.72M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 1.113B |
| Shareholders Equity (Quarterly) | 512.60M |
| Debt to Equity Ratio | 0.7009 |
| Current Ratio | 1.917 |
| Net Debt Paydown Yield | 0.92% |